close
close
Shark Tank judge Namita Thapar’s Emcure Pharma gears up for IPO with Rs 1,952 crore IPO

Shark Tank judge Namita Thapar’s Emcure Pharma gears up for IPO with Rs 1,952 crore IPO

1 minute, 46 seconds Read

Namita Thapar has spent the last few years evaluating all sorts of companies on Shark Tank. Now she’s about to have her own company evaluated by Indian investors.

The IPO of Emcure Pharmaceuticals, whose Executive Director is Namita Thapar, opens on July 3. Through the public offering, the company plans to raise around Rs. 1,952 crore from investors. The price band of the company’s shares has been fixed at Rs. 960 to Rs. 1,108 per equity share.

Thapar herself holds 6,339,800 Emcure shares, representing a 3.5 percent stake in the company. She will sell 1,268,600 Emcure shares in the offer-for-sale (OFS). At the upper end of the price band, Thapar will earn Rs. 126 crore from the IPO.

Emcure Pharmaceuticals was founded in 1981 by Namita Thapar’s father Satish Mehta and he still serves as the company’s CEO. However, Thapar didn’t join the family business right away — she became a Chartered Accountant and then went to Duke University for her MBA. After her MBA, she worked for 6 years at medical device company Guidant Corporation in corporate finance. She then moved to India and started working at Emcure Pharmaceuticals, where she became CFO. She was later appointed Executive Director of Emcure Pharmaceuticals.

Headquartered in Pune, Emcure is a leading Indian pharmaceutical company engaged in the development, manufacturing and global marketing of a wide range of pharmaceutical products across several key therapeutic areas. The company has an established presence in key therapeutic areas such as gynecology, cardiology, blood disorders, oncology, respiratory, central nervous system and HIV. Emcure has a strong global presence, with operations in over 70 countries including India, Europe and Canada. It has 5 dedicated R&D centres and 13 manufacturing facilities across India. Approximately 50 percent of the company’s revenue and profit comes from overseas markets.

Emcure’s IPO comes after a few muted years for Indian pharmaceutical stocks. However, the last few quarters have seen a wild bull market in Indian stocks and the election results seem to have fueled the markets even further. So, while popular Shark Tank memes may show her “looking” for most investments, Namita Thapar is hoping that Indian investors will get behind her newly listed company.

Similar Posts